Surface Logix
Founded Year
1999Stage
Acquired | AcquiredTotal Raised
$114MMissing: Surface Logix's Product Demo & Case Studies
Promote your product offering to tech buyers.
Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.
Missing: Surface Logix's Product & Differentiators
Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).
Surface Logix Patents
Surface Logix has filed 9 patents.
The 3 most popular patent topics include:
- Abandoned drugs
- Clusters of differentiation
- Drug discovery

Application Date | Grant Date | Title | Related Topics | Status |
---|---|---|---|---|
7/19/2018 | 2/25/2020 | Transcription factors, Proteins, Human proteins, Clusters of differentiation, G protein coupled receptors | Grant |
Application Date | 7/19/2018 |
---|---|
Grant Date | 2/25/2020 |
Title | |
Related Topics | Transcription factors, Proteins, Human proteins, Clusters of differentiation, G protein coupled receptors |
Status | Grant |
Latest Surface Logix News
Feb 13, 2019
%PDF-1.5 %âăĎÓ12 0 obj > endobjxref12 210000000016 00000 n0000000913 00000 n0000000716 00000 n0000000990 00000 n0000001111 00000 n0000001289 00000 n0000001410 00000 n0000001860 00000 n0000002392 00000 n0000002426 00000 n0000002653 00000 n0000002874 00000 n0000002950 00000 n0000004000 00000 n0000004988 00000 n0000006021 00000 n0000007038 00000 n0000008088 00000 n0000009062 00000 n0000010120 00000 n0000011073 00000 ntrailer]>>startxref0%%EOF14 0 obj>streamxÚb```a``ř(ĆÄ00TX-ůĐ0HÁu7ba°kÁÖÂňť˙°^üÜśřŐË*oöóŮÜÂ43Đ@ ô¤endstream endobj 13 0 obj> endobj 15 0 obj>/Font>>>/DA(/Helv 0 Tf 0 g )>> endobj 16 0 obj> endobj 17 0 obj>/Font>/ProcSet[/PDF/Text]/ExtGState>>> endobj 18 0 obj> endobj 19 0 obj> endobj 20 0 obj[/ICCBased 32 0 R] endobj 21 0 obj> endobj 22 0 obj> endobj 23 0 obj> endobj 24 0 obj>streamHTŰŰ6}÷WĚ#UŹę.=z7ë ťĆĘčćA+Ńś YrE9ç3úĐďípś×)ĐÚ8áÎĺ˙řĐŔDz2ČńYä{yqyiŽŮFjňşÉN ŇŕÓ_W¨yˇňaŁ/ţŇĽŁŔĹ=ůý|úśź)1ő$őň $ţIđÓĚËHÜË2Bą;ß*˝D|ÖčvźUIá^&ŐÇżNgsX>ž[|éěn1˙4_9nŚ^"oďçłbpž÷ #ÎÂQˇ@#Füź(î`ľüâFN"¤ăú^,r2,Ŕ1¨ď9SĆtO xŇüŕĄÓĄgËĹĂb6]Bńa_rTJÜŔó,>! ć !łÁÝ>ŽÇřÍq#¤t/Z{đ$XsO˛;Jž8k"ČłîćJ)Y)3Ú=96.áĆůYvŠ\xIϡ˝żŃ7°:ëÄľËÖMóFëňČ-ťý×]j[ŕÓÝ?řUydĆě)řSŃÍčd¸mĚ6ß2SZ'ĆÍčHüjhh×Ů"[ňW0ëIŘím5ixżľŐ6 )ŤH@Pră^á5UÉZ6l°Ú~ÍžŤĺwC6ÓC4ŰtźR_(ßčŻoóŃ?Ât.Át ÔŽ!-^,ćž'ąĺ3Zś6VöŁô¨+CŮŠŚŘŞoOhĐ$e`°Ě g6÷=ŤG'Çe`kš{rŻŘŞŤzŃĽ˙9×c0-EW÷´îLŐsńCŃŽžţđLkŤ\+đšÍ7°oi_Vęšw+ĆęFSŁnMSaAÍĆÚćĐăáľőČý.ŻűŇp3bác|źĘ/ťô;äü^đpČ AČąxKTuŰyĎŢÔĚ`θsąëiéô8ŁŞ9ňq[2(žH˙?§šZîâ UyĐŞśrKŻPCßÎóX}{zĄl:^ןTütăé%°ńü˙K0đ|ÖjäŃë;ÍIFkßëç{ŕÁîj;¤? íĆíĂľ ş oIˇtÜCuĐL=Czý`đc¤šDŁek˙RjxaÖÚŽČđďÂŔÔ Ĺ$eg×g"Ŕ\[óásاÝ^đţ` Hěđendstream endobj 25 0 obj>streamH|UÍn0žç)ćU@ŔÂf97§ŞHAÍĄęÁłXLąˇ}ô;?&Q5lgćĎCóĺ*ŻŇ}As{diöĐŻžG'7é>ŇOj2ń>5řASńĽ˝öë áă~mäѨůvUd2Ňő~4_Ž *ÉÓV$ź] M+ĐY-ĐzŠ˘AjíO3óQÇdyWiľçbłď5Z/;Ë:Á"Kâ|Ë>ÎđĘŹĄę,Á@Q~\Ď~ďDi2ł\9ŻWÝńŹz4$ăę%ă\śRśx%îÎ:Ĺö\]¸˙Ę*OIÉkVgźćĄîT˝V-bđ¤4ĄˇĎ7ßG°+HsÔjč¤ÍXşf=*ĺ,-IiSš¸ˇZ˛Ě¤ĂĂÖá2Í7ë3 g2wZÔ"-ű¸FĄ;˛ úoľÜĹ.źŮŔÝŔŤrGqNôOÝ K[*.Ý?a^ÔĚűpŔ,IF f[#!BwqŁŕ/ĚVÜ÷1ž)ĚÔ§ÇÔÇÇ&Ąp+p6°ë×I¸ľ"ăă{(X×4N¸˙zVőĄzAGĂçAw~7HwAćQŕQĄľVŁŕĄÍY¤ťzĘLŰłBĎĹűKlę{âcŤZ#O$Ä76wA_ĚW"łĽ Vĺ%˛xD1/ßS,(Yfc˘ęTXqŽŞÁŔCĘvľĂä1Ň1ŽEď@C/§ˇĎŕoE=*°Š(ËŐCTxđÖłhVüţČnju>ŇRn pż íJĆu řF"¤ÜjöwAQ,LZĎo˛§§ ĎÍ'1$ŠCHą Ą("ez˝qŻo>oţI,ĂÄ~ëvp"YAŇš?=ŃŻ \JîŕŤĺőhRx~Â3Î[Ů-ř;mOâ\ Ö:śXăLŘjÁiążĆęí#łXÂŁ@úá%šďüţvüżĂĹńßiGý˘#Îü# ąrzv×aŻvq0[žö`Ĺn-¸Ĺ:żđvUŇ:ŤsůA˙ghĚ%0Ŕ÷ÉŁLńŇę éđ'đ(ĂCPwö^/ż6'#ČĚGLţ0 MTîGendstream endobj 26 0 obj>streamHlUKŤ6ŢçW]M5 `ÝŞ^ÔJ7Ň]T]8`o FŘL~Gďîy0dÚ}>ďóy˙eguҤMqdyĂţy&iş`ßnbşó˛ůS˝Dť¤VĎję%nŚÝhřôQźM˘ áËZ-nDYŽ`Őycô`?|gę,Źćóꣿö_6Ů. )wuéGĹGi#1&đŰivřŞTKĐESŞńúQěÔןaÚŁmŠyiňůÍ0ŕĹ&Áźo8ř=Ď ËoAUÔďśjrŹëmT&Š2,ŚęäôÁN,;WĆ Ě$Ó/îaĐĚQ:ŕzÍ#żŃ9¸k.žđúÂlăž7m'nyd%2L]Ý˙ĚyĺÍ-ŻBňęŁZ§6P`CÁřŕŕăĄl;H=gźő˝Ť)Ŕ Eč0Çöá˝ËMˇ.ß\öYtšÓĚ7wřěŕ "+ômW[ŽŠc ąćëa\Xî+cIĆEńÖfçs˙;{3áĆbéŔĽ(ĐůIݍ1&ě3ěiÖŘ÷AFńrB]ľKÇú2Ľ˛!ů!ŚŐ+şüÍkělţĹ,ôč̲F{ÓAŔ@b˛ě,çJśăĂŃĘËVbě*đ˘xäě×wň;.Ć/Ŕ˝éă`t$~U{ áÍŹ˘ DĂLÁ?XDě>*ôŘť|wë]&ZĎ>&X*šÚWÓÉś jĐůF˛ÇxA:ČuĄ~°Ńx]'V:x^iÝ7;Vŕ ĄŚZłĹ/5=a:ČEÇż÷˝˝háőž[ÉíöÇÚéŻçĽ§bJ^âćŲo Ť¤Ášž˘ĘXżupTaŘi=ŘÇѡ´|éäl#!xĄ;8ĎbB˙m@őôcą×xmÍb;žń@˘sžő. [{Ç33ÉĚe2sÍwgž.÷[Ő&¨YŐѸ4jĄxÉŹZăěVyHŕWšâ Tˇ÷ňFf'D´žW°ňŁ ßs äănViq?Ł_łŚ{dx˘d*ĺ.+va0jcůśLÄf] ŕÜ(/qćpŔßbÁŢ:Ióźě (ôZendstream endobj 27 0 obj>streamHdUÉă6˝÷WÔ,AűrS0oÓ9Č2m-Eť[żäSeuĎD˛öŞWOI$yűţ%JđڰůŠ]ĹľJÚä_?XZňfâŤ×)VéD4ŽăJy}wgĽYG 2|w#ĘgQž/QJG+F3čöžDi'YVC˛4ýˇĘ3Ď)'ľ¤ě(FŽnÎĚfňşÁó,>;3'~r5XěMówyHKeÍk ĹÎJ˝×ľšťĄAXFç%5÷0!HíSéúOM Ęâ˛mĘľĘ4§*ůI?žDýG9ZÎüC}q§ŁÚĚyY×;qŚqT)$Ťă¤y:ÝěÍËěÍu ZsŐëýwă(× ŻĐ=$ă.hÝa4Ď mŢ[tQKaşpâ:Ţ:ň éÚčRžaďělŻÝ(ˇ,ˢ,CBą!Ą(4łR98Ď#öşĹüs`O@ŃpxÇ(Ő|"śł^4IÖUí˙~Őŕ/Rs'Um5çĺ3ŚlUv˝ĂńŔ2FŁĆąőo¸#j:c'뎧;Ë6'ö'+řÔŮec}\ĎT9öÔK8fčuˇÉžSL\çèżHŰuŔŃL_8Yr#ę¸zĺNëĄA?ą¸Ĺvá ňLÉĺ ą3G!^¸c:ŹVpżyöÓ˝Â˙Ę$Ş' Pż §Řŕš.×-Š&ÔpČý˘8#ŕÔ$"ŕÔe:ň°Kôľbcp\8S Ú|ű$ŔwËőĆŚN˘#wHßĹÎő÷ąc"ŰZ /4*ţáÎ10łX!fĚçôwXRťş˙[,ŇŔ =ôöNťÄŚ#Q5ĄŻß˛édükAćĂ8Š×q´ř&Űţ0+,g0'Ü9âAdĺŐĚÓ¸Ŕ0ń;ůR3 8óNbý Ôę;?Č8ŇWđ˛ŁXé\~Ľ|˨پP>r8ňmHJÜŤé/˘Äź)˘ńfŐ!Bęą1Źů! :˝|ź|Ěr~h:¤l`äçŕäaÂ/ćU˝ăOư Öůž8G˘_ď3{ó{)§Îűĺňv[˙0 óendstream endobj 28 0 obj>streamH\Ënă6đŻ#YŹ=,K>.°§E¨oé$ś U(¤č7Z ßŰyĐv6ćý>ŤYďóřűŞł:oŐňşÎ÷ęo şEŘťQ~xanÂüšw\üqüÄťÄĹě#0ĐY7ęŐÂ@ÖŹs_Ö3âxłCr{ÔG"čÇďOÇßź(ŞÍSFżĹoOĎjÔ{#,Qwęb1aö"k~3?a2ýĚË6/ť˛ßŘwÝÜ}âNśÇxŃ.Őęí˝f:ŤZ*čĽÇTŃ*R1{âż-ŤaĽ2ËęÄJmvsÁUYÝB(8}`/!éěŚÓdtśĎŠžXťŃľtŻŢ'íňJľ0Ĺ%=ë]HDN! ;4ýł`¤"Mž˙Ľ"ťö^ŞxfÔŻPżeőţŢĄá/bůí" ,wŢ86Ö°¨^ăhŢţ+ĺl˘,gŃ}@Érj¸ŕţVĐ;´ëî=}dPڍ]ŰŇ)ťe2p]K¤ń9ż~Ďv!\@Ě,4Ҥ+Ľěň˘lŞĽ|×!ľÖĹWŚP3¸%Ââ0{ľÁä8oĐqD&Ń+N#3íĆöAjXŠ,w´'°$ )PčÓÄŐőcá:kÂ5ęxvŠWr5ešA oyĂĘ`IřD7(iaĚÂŘËŹĂ÷:ë°ó˙°Y´&EźŻNýę8.wˇŃËD Ľn¤¤ďąý RâÜ_Ł/ˇ´ÝĎłJÇŐ¤äĎźŐ;äŽb8ö?í#Ëä˙,íiXS˛LI+ݰďO)§Ä!ôL9ٸĽ_ŕé&ÔjŽŽP|JZ0˛đ"Â+ZĺškŐăBqlć î@°%Âߟ럲sŽŐ0ÓG4YŤ.Ş@Ö@Bsčű>Ě)ń|×ĘŘĘ8Öôŕw`3SŹł}?Ď,żŃőČ[~ŚRă&Ç´hCLŚ-_`č˝ő2ĂhqgAI|G+uÁyú4_Š˙8úB˝eűiévl-ďH;"pu#Ăđ!ćßKŞÁ~-D+:ä fňféŁqÚ˙4Ď >XiI§đ łFň$ë\*0ÁBěÍĘ1BÔ?ŕ ; éendstream endobj 29 0 obj>streamHtUËrë6Ýç+°:ąFĺHŢöŢM;é43ńŽÓMS6ďŐĂ('ţvÓż-CůÜnL7ż>l~zH4]V´Ń/fKÚź=üőńS˛Nń2Š"3h\[#Çă?ÉS4k[Óš¸bÉěč+ŤŃ/$ŃŇťŠ7z}Ó×^ĹšÚGúr 55źjÓÎA¨ă!ëxáÁÁň÷xw°śÚpř^§ĄVÚPüçću~É:-őłxî÷6^1˘÷ţţ =.ŁÜHHŤŃoÍăŚß6/ń"˰ŘN^v+§ĺGâÄQ¸ô0yźâň>_ÓÉ7Rys`´WŁzŘuÎŃÓ]D.h(űdk˛k$ë¸TKŽŇ:Ő*r¤FRČÔoĺSű@yÔpŽśĎ%ă$×vräë 6° Ľ´ůú=Hý$5ŕíŻ í7@u? :éŐVŽšp6ŔŕhŕÉYĐĎg0ł1ř4ň,ż ůL˛?C:ěěA `2dŢfpHťdÎV÷eÜâą?ÎŁŐ#őľTĆV!HťEiîX_ŕ/GčpŮ xĄť{Τ´ îű¤ź!GňŰÜň¸ůŚŠ¸mŹXEÝČ#2@ö9Yc Laf*Ç Ť|.ˇbß ˇeámcôĄ˛Áą?ÓKruźć{§ŃĐ>Lofnţc;|^a4=Łźëaම7ˇä°*hgFLçžć¤űöŘOŘ)WŘäÔw3Ë|Tç ĆËŁ{h^QĄóJ|éKĎtŘAaű p"ůŞúÁTVa^ß LSşNÉÔ5ŚRă/ŔÖüLŠlyúWŘźě§/Źhý#ŽĘőľřůľçęˇę'sýŚďŃMíśű_ąnOáŢëď Ą>úóÂ>ąŕążýˇ:)$×ŕ-lÜ-¸8#şé4ĘźöĽ0;ŹŹízń˘š˙ÓlßěÄ+ž$˙ŮPY ?đ0}Lżw~ s3w=7+ČÓXśź´żDża ţ` ťäřendstream endobj 30 0 obj>streamHU;ă6î÷WLI'EO[žîŤ°ŔŞ;¤ %ĘÖE˛×÷;Ňäßf´˝Ů-R óüfĂ4IÓbMű§xĚ2h.OßędŤ\T$ 26ČÍeş.ĐÚi2ŽĎ!Ú&u˛>(Fčk§üMĚ$ů˘?ßRó¤ÚŐ4_(dqVźAwľ:pMÉččŔ7ŕÝUIĽtgHFfŕäěYî;=ÉÔ*Î 'mź(kHoI䤥.+D/ŘZdE§ŽÜ$2Í~˛S`{4Ů* `tz?ż~p.ń-´Îň,ż×eűčJ. )=5"Żš/Ľ4śÁ¸$ĂĆ´Çٲxr¸Â3Ő>WÚSjîĐ|oÁ°ćŹ÷˘hŕeu˝AČ ř|ݰ´C0wÜç\-c,wߎůEŔT0ĽCŁ zążĂ* ĺdh°Te(ćQbáÄ:Gí÷Ăü°÷ŹĐ¸Ţ˛őD§5L `fZt'¨ĹEťŢpÁÓNäv¤Ś˘D,ěcMX˙\ ?ÇĂ ĺęN°Đ¸ęcśšš˝S'ÎŚĺîÔ9*ąÍ89(źŹŹŕúhGCßęÝD˙ëNŽ/Śc/ßžĆ%ÓtĘýEěüÂ!˘^`Y>üĹdŲPř˙i¨yôĐËŮI#ÚŤ71 ÇFiw0rşnÖŇŐĘ"TŰuĆč[yˇ8v%Ž~ˇßt2ŕé7yŔŕĹ!oÖÎg3,$ĂvÔý9ďcZ`ĆťŔËuńfhRzz ˝2úĹôRtĐńĄř˝yŚë*Ŕ˛9˘çvÜ>PbGŁSĐ>^Ä]"ŠţÚ4%`őűK5,4,/č)W{ťzZ@ấӜý|ó¸Ű$+6eXź`Ćͧ8ß/ňŤÁ*WęíůČkC/rŮ1°řľĂĹČ>xLć.hNYë˘oÝĎęěÍÖ.ŢüuhçRÓsÇ'; ?M÷IRčěĘŘxĎ'~ྡྷŁ+1ü$=ˇšŐźĽĄÄtv ťË0šô |o˝fɢÝÓ@źd6$~]äĎÓĐą gŻ˝ýfť4ŤŢüfőŁ. dËş˙\/ţŹ=ÓŐĘđu~,ććŔY'üHŠăŘÝf¤ŘLţ×đăËÓ%8𠘺Ľendstream endobj 31 0 obj>streamHlUM8˝űWôQ¤0S5ÉajśvŞÂm&dLČdĎňďˇ?ŔNm튼Fę~ÝzŻŠwarŞ8É!L˘$MR¨vqÇűÔÍ.¤%9?vojě 8D ˛'ąß_"*Ő?aĆ6Žbś`g¸đj0hŚtcźˇ`ŮNĆ-Uc Őěč4ŠZčŞ?łk6lřżĆáiYݧpUNAIą)ćAÍ-É ĺűZR-.âSü¨wő'.1-ď%Ć{)ńŐ: r;a%x6SŰŁÝ+=°?ËžŁjXłzZůa$ŃhwMË{Đ^Ŕfó÷]fZ]ýÄ{oć°PŢi.ą)%oÚyńMr đżś/ŻHiôXőDWrő6gŢŰÁ°uA)=:(C-CřÚ(řĐN@rTJä%ŁŘŽçkÓ´ÚÝ §Vf[l4ňg#çŻüĽ Ë?8ťůŚ(rą]čNTßąďěŁ WŢś Öą¨ĘćęśËô\vâ=5 YŢqąfiń]#É@ tČř3čöffˇÖgnřŢ7-*j÷!Up9k^ĚŁně/zŮBMĆs žÔáUZŕM9š8^ž´^í°&Zháŕbć]Sś|BFrMweéůNHÚŻĹçşÎ k>íb@6ćU\Ý[ńčD.ř ru´Wß_dF$4#śřđ´°Ë ýĽG ˘1Ľ{-ÄĂÁ_G#§ˇ˝_6$ I(ÍĹú("Śü(úç.Üž2Ú2ßĐţň# ćŞw ňÉŢĚ Ŕ'; nqŢÂ,JKqçDĘŕČDî=JŐĆJŽd AYgG=Đ8ęE>Đ$jWÂůYOîd3Îô9_§ő'|őߥ=ŚĆúÚö4+ź!MçjđďęĎúő=¸Nű#[PBâűpÜŽvěĹ0°ÇJŮ)¨¨&é+j´Ź~×ZţŔ&ĐčW!ÂŢŞ5Z´=Ńą3ěvqX \´+Ůđó;BGOw}wđŻ mŘťendstream endobj 32 0 obj>streamHyTSwÇoɰĂc [°5laQIBHŘADEDŞ2ÖmtFOE.ŽcÖ}ęŇő0ęč8´×8GNgŚÓďď÷9÷wďďÝß˝÷ó 'ĽŞľŐ0 Ö ĎJĹb¤ 2y.-;!ŕĆK°ZÜ ü^i˝"LĘŔ0đ˙-×é @8(ľr;qŽŞ7čLöyĽ&Qëńqś4ąj˝ç|ć9ÚÄVł)gBŁ0ńiW×8#Š8wŐŠő8_ĹټʨQăüÜŤQĘj@é&ťA)/ÇŮgş>'Kó ČtŐ;\ú ÓĽ$ŐşF˝ZUnŔÜĺ(4T%)ëŤ0C&Żé¤ZŁiżó8ŚÚbxEĄÁÁBŃ; úŻżPŚŢÎÓĚšAüom?çW=xŻÍúˇśŇ- ŻŔňć[Ëű 0ńžžřÎ}řŚy)7tažžőőő>jĽÜÇTĐ7úż@ďźĎÇtÜň`qĘ2ąĘę&ŻŽŞ6ęąZLŽÄ?â_řóyxg)ËzĽČçLUáíÖ*ÔuľSk˙SeŘO4?׸¸cŻŻŘ°.ň ňˇ ĺŇ R´ ßŢô-2đ5ßáŢüÜĎ ú÷Sá>ÓŁVdĺ`rŁžn~ĎôY &ŕ+`;ÂA4É ä°ČA9Đ =¨- t°lĂ`;ťÁ~pÁ đGp| Ž[`L`Ż "AYA+äůCb(RĄ,¨ *T2B-ШęĄĐnč÷ĐQčtş}MA ď 0ÓalťÁž°Sŕx Źkŕ&¸^ÁŁđ>ř0|>_'áđ,ÂG! "F$H:R!z¤éFQd?r9\A&GČrQ˘áhĘŃ´íEŃ]čaô4zBgĐ×ÁŕE#H *B=Ą0HŘIřpp0MxJ$ůD1D, V˝ÄÄÄăÄKÄťÄYdEň"EŇI2ÔEÚBÚGút4MzNŚČţär!YKî ÷?%_&ß#ż˘°(Ž0J:EAi¤ôQĆ(Ç()ÓWT6U@ ćP+¨íÔ!ę~ęęmęćDĽeŇÔ´ĺ´!ÚďhÓŚh/čş']B/˘éëčŇÓż˘?a0nhF!ĂŔXÇŘÍ8ĹřńÜkćc&5Sľ6ťlöIaş2cKMĚAć!ćEć# ĺưdŹVÖë(ëkÍeŘél ť˝}}Câ¸qâ9N'çÎ)Î].ÂućJ¸rîî÷wGä xR^Ż÷[ŢoĆchgŢ`>bţů$áťńĽü*~˙ ˙:˙Ľ E ŇbĹ~ËĎ,m,Ł-Ý,ŻYž´ÂŹâ*6X[ÝąF=3ëˇYą~dĂł ˇŰtŰ´šiŰzÚfŮ6Ű~`{ÁvÖÎŢ.ŃNgˇĹîÝ#{ž}´} ýý§ö¸jĎţc1X6Ćfm;'_9 r:8ÝqŚ:ËO:ϸ8¸¤š´¸ěušéJqťťnv=ëúĚMŕďśĘmÜížŔR 4 önť3ÜŁÜkÜGÝŻz=Ä[=žô=Bş0FX'Ü+ňáű¤útřűG,ę}çďé/÷ńżŔHh8đm W 2p[ŕ¸AiAŤNý#8$Xź?řAKHIČ{!7Ä aÁa°aWď żż@°@š`lÁݧYÄÉH,˛$ňýČÉ(Ç(YÔhÔ7ŃÎŃčŃ÷bűL&Y&9Ä%ĆuÇMÄsâsăăżNpJP%ěMIJlN§|ęŞO=§%§mLť˝ĐuĄváx:HŚoLż!ȨÉřC&13#s$ó/Y˘ŹŹłŮÜěâě=ŮOsbsúrnĺşçsOć1óňvç=ËËďĎ\äťh٢óÖę# ¤ÂźÂ łăoZTÔUt}`IĂsKV-ý¤Y,+>TB(É/ŮSň,]6*-žW:#Č7Ë*˘Ęeżň^YDYŮ}UjŁęAyTů`ů#ľD=Źţś"Šb{ĹłĘôĘ+ŹĘŻ: !kJ4GľmĽötľ}uCő%ŽK7YVłŠfF˘ßYŐ.Š=bŕá?SîĆĆŠşČşşçőyőŘ Úkď5%4ýŚm7lqlioZłlG+ÔZÚz˛Íšłmzyâň]íÔöĘö?uřuôw|ż"ĹąNťÎĺwW&ŽÜŰeÖĽďşą*|ŐöŐčjőę5kśŹyÝčţ˘ÇŻg°ç^yďkEkÖţ¸ŽlÝD_pßśőÄőÚő×7DmŘŐĎîoężť1măál {ŕűMĹÎ nßLÝlܤ[ţ¸$ühŐBŻ÷dŇ@Žú i ŘĄGĄś˘&˘ŁŁvŁć¤V¤ÇĽ8ĽŠŚŚŚý§n§ŕ¨R¨ÄŠ7ŠŠŞŞŤŤuŤéŹ\ŹĐD¸Ž-ŽĄŻŻ° °u°ęą`ąÖ˛K˛Âł8łŽ´%´ľľśśyśđˇhˇŕ¸Y¸ŃšJšÂş;şľť.ť§ź!ź˝˝žžž˙żzżőŔpŔěÁgÁăÂ_ÂŰĂXĂÔÄQÄÎĹKĹČĆFĆĂÇAÇżČ=ČźÉ:ÉšĘ8ʡË6ËśĚ5ĚľÍ5ÍľÎ6ÎśĎ7ϸĐ9ĐşŃÜÝÝŢޢß)߯ŕ6ŕ˝áDáĚâSâŰăcăëäsäüĺć ćççŠč2čźéFéĐę[ęĺëpëűěííî(î´ď@ďĚđXđĺńrń˙ňóó§ô4ôÂőPőŢömöű÷řř¨ů8ůÇúWúçűwüüý)ýşţKţÜ˙m˙˙ ÷óűendstream endobj 1 0 obj> endobj 2 0 obj>/Font>/ProcSet[/PDF/Text]/ExtGState>>> endobj 3 0 obj>streamHŹWIHžëWäĽ'=ścş;ěn%ÇĘ}@čAŔ Ş*Eôˇą¨l/S!ryůň-ß[ňż+_jĺšIáO%ĄďŚŇĐ#ľĆi¨ÎŽţęŐŤ7ýFĺ˝ňéżĎaĺ[_űůźçF#ůüaőŻúťŐŤÝÎ ÝaşI¨jwnőčoőÔ.ÇÇVÎîĎŐ:r}cÔ:pĂ Ü˝{+ëpÉ/ٸqBÇiŕqcoXř^ ×{ýsăŹýŔôŮ:ě~]˝Űąoś"ÁöÍopůŻ0úÔő6ę¤VÔý*Ř|YňźňŁ 7ÎŤŐő&ĐH2Ë"E1DŇĽŐ˝×ę/ERĄSâŔ2 @đá×űćĘyŽŻőšŐ{Îô7ž/tHR7ţ#ÉBÉc¤NęTÇYÇ úXś ďn´uÖĆMtUÖýgťűiäpËř)âë%š&[Űnfa śm×ꨢ+'v 0IőĄéßčó(1ş~$ňÜŕ$ˇřÉ$Čč§YŹjŰőqş7ÜtyoB/ß;üżŔEgÂpDĐéßŔs~|ěQúDŤżŠw7ýŕxzÜŹÖD/˘Ď¤ĆMÍŹe¤kSËä[đ#ČÍúnĚ3;żq aXt=důMxLčBĐ`ž NÜŕeŠâÖôÇ}?úJČ=ĄÎ0îp!ąÁ_MIŕ&DzÉŹ4ÜĆŁ3˝XrPżÔÖItéDpí`Ő¤ [ qŃR(ÔÂ(a|9UL$K_=Ké!ňľö]˛ç4?%dIˇîĺ`Ą 1ćÖę}s,őF?ŃęłĆtŽżÔš+śĎëŞk'ýT-§ĄWloť[¨7 ómŻÄŻ+9 ČߍgaUŕÇľ^ř-Mç"#ćń$ |TÂKŽĚdŃWůäj*K_žtMâŁĚMžľĘęBA^w˘H^]sČ0Ĺh@¤VL,łËSáŤJŐBĘ׏Ú37\N!H˘˘:ŃřüĹqŐŰ%ß^¨-_ŽF1mžÔĹmjâŞĘŠ9S>ÔNHčOćń7lĘxÖ5ôÉŻ2ďď Ëśďiú´éëĽ}ńRüJÄ= #$Ű! @pşDÁ)ˇl'cuiikČţ&ĂáE$W`ěë˘WV&w˙Î6?ą Ĺ?ĺŇuĎr°ôů#VjęĂîăhéoîKöG)7 CŃöÁvj!Ń bA1¨ŐÉźs ďëcĆź{Ő_ňőˇŞĎŐŰęŇEh"!ŇJç-ŠPRę";-ëÍCÖ]1"č˛WëňeŰt˘Ër1ťšÓ@:Ź0Á&Eđ=ú-ÔGDH˘{'DëdĎď˛O-Ż6΢q`ŐĽˇGśďÖ$ĆzăôšŔůRŕBâ(Ć/;ž š)Á@ä˘;uśCF+{)ŕ.ç{Ś}Cť]ÁÇşţNńFÍňęÂ[rĂQ5{&íËáŞ7!°ĆŃv°b#Ŕ}Ş]Z.ĹS7JŠĚÎëç[rŘY@ŹhVb¤ůş,,}ĎĚż¤˝ĺţůĽëlMűăĂJľd$Đ;CQč,3b3MĄý§ÁOÜÄÉő$~;2żfń@ąLM{áyĆ,Ëe¸#Ô#9öMôÓďd˝ EŚpH) Ax§¨ěc¨oŔśfřSö@čŔužCJxČę :ÎOĚćČL+\L29ď ŕŞřű Ě{WýBÜjf .Ú.EČ7Y0´MFřĂe>SxĚČŚžÉF_^lŢ1c Bă÷˛|TmjłlŃż&śD(>Ű 8Xž-ă¤Ň M8§ $I¤6ŞŞŕrÝâOÍE¤×çŚ ˝{Ă7A¸˘ť{°DČšíŃéSŞ /Đ+Ýť˘%ú9 É FĐhHŠgmĆŰHXsís0¨ÓáÚrŞş:ŢŚüëSţZČéeëüHiÔvŹMŰttySĎA@1w*á~÷ĺ1Ę>9Ţ-/ĽĽ/"Ų~â^WŮžŚAÓyŁ2ßđšěÖź%Ż~J ßÜ6-íwÍ`ye¤ÄHć\J! ŐgwëŢÝVżšöĽţĐ nŞ'ÇÁT˝En-48P ú÷bY ŚüŐIË`pnĆŮpÚ ôGÚSçĄr×g(ŽBZÄ%ĐľnŻćĆĺ^?Rq/šcčqâdŚhŽŃĐ÷d7č˝ÚiŃn4ó˘peąKĺîEÚUżđh¸c*Ôq3žI."ĄŕŰŞJd¤.śVLÜ9řŹ˘vzZ^¨MőBG´ŚŘÁDPąŻ^čQڧŹ@ČŠ,ÖŘĄ`e GĚŚŽXuMĺuĆWHřѲ@ţE˙Lóˇďż8Xż ˝B×@6;8´!+ĚĹť:XE1És!ĹOsCL/{p|úÓ3˙ˇú";Jvú}/í3*) '@Ňč/űe>8ÍÔ'(ŹřÖĄĺBť@ÇÍ $)ľěSÓ 4Tfhđy+âFú§ĺfPçt6~/I%GC`EşGŠU!íçkNË ĺĆ'ÓU!ŻŘlŕ\4ěÉ|j.>Š#ćÚĚľG:ąŹ1x/ÁzETÔŕo ´ú#ÇĚąďPß/ĺ§ËßţźAßfÔżşH,XŘ÷A:jŔÖüŃö xźţ§UĹďGĂoŔę8yVôűđÔĽóűËŔ+řĚHč˝9ÝĎřťę8VNĺóô¨°ÜGdmşśĂVůĺIFíÁť žéZymĹ,+çRśę#ˇŠüžÁgcĂďU0íÂVĐ3ÂBw¤/G~ 1l#~ÇĽň41żă˘9ÝLϨĽRCu2c{/0¤.Ő5wÖ>űŕ´HÁEąŚQĎű-M ŤĂ uő2â ˝>ŕŢqFoQ5lnżŔő×R!ŃS+yŽÜž5P#5żG*VB!ńcÂÉ@š| Í"hąFóÔńąČ$$¤Ę ˝éÄH~3Ă%fĆĹ˙^5=n"Aô>ż˘X˛ ĆšeiEľ{Č^ÜŮĺK=ăŞWĹöBÓTUQýŢŤóRJJĸ|}nWu-äÔt§r$TňRĄÂFłg,§%d ÚĐv¸˛tŠTŹĎśÔ°VĽ"öý~ż6ä|Úc7çˇz1:ĄŮGJ¤Îü85iXóT˝doâÂ2qű CYŘóÜČ" ű@#ű UÔzÂßa[â'V ăIî;áˇvjîńEţ}ŤĹB´ľA,ü łÎłŕCU/mÖŁI2ĽžťB.AF,#]ĹĂuH§çĆńÁňÜĽÉ!ý?1ŇŚ¤¨§?Ą$ŘÎMKGa¨IŐ.UęČ×uZŹÔvÉ)WoĽŘřÇů&öÝ'D"DÄŤ|ĘŔÉ$VőznŽKpźzoźE[ş*fVW++ŇŃž´ŞŘQ÷,rtäÓŹPôÄľőŚWómĎEzŚI°ŽJ0ŠxXú2Ń %ĚŞ6n¸šhĐđ|JŠc-˛x(HD§MUhńGXŕOd=féVřiĂRŁÚKq-ËĂ 6â -'¨köÇáUQǰBă2ëÂÁs=Ăç^Đ'$$@c~üH¤jĘĐyá)NÜH`YXăÝ ˇó'{đ`UKĐŐ-śĚ X˛Á~EkR_a_lŇbîÁ`őҧ]ýb*ěF +|ĘŞŃł6áÝ=R:2!nć3ĆŔšćşQz˛+,ÓműĚdEVśTČnD+ásÇhan2źšČh#ćň 1Kłg1ËpËEÎ\ÝeůK?¸čoń ŕĹřjľu!ó?óŞ+ uŁŮRTź=]CýB~QHëˇxÄ÷HSˇsí¤\Š(""šŠĄŚ×á°śg?ňfĺEˇĺ¤ŞuÎZ!ţlŔ¤ę'`íę3Ďšż}}u[aň( jyÎKWŰ}Úţ%ĆMŕ MqçoW~~÷ăîaˇqˇŐĽÁË0fŇ9c0ň"pAc%MşŠeŕ×Og'Ş˛#ĽđáĐţ:TVŽ`÷éňˇ}n;Ű ÔóŤ"óýč>şsB%3ĆEďÁýčkY:ęh5äál˘ ŰôBz9űúö/J×, kžSY$Ënnv˘vĄşjŔaÄuâף=OgǢyKLčŽv_OkËRđ}Ć ˛YKß/Ëq&OąźUň{:_-Ý ÔCďţŠ?0n´â¤ŕÍ.>#úĄI¸(_ăQx$1áT§HÖ9\6%2¤ý!KDǨe§BÄűŠěí¤ŁËvÔUďmŘDÍ_´Ő2nĐŻ 9koendstream endobj 4 0 obj> endobj 5 0 obj> endobj 6 0 obj> endobj 7 0 obj> endobj 8 0 obj> endobj 9 0 obj> endobj 10 0 obj>stream sanna.hug http://www.surfacelogix.com/news/news_080129.htm endstream endobj 11 0 obj> endobj xref0 120000000000 65535 f0000013742 00000 n0000013867 00000 n0000013997 00000 n0000017810 00000 n0000018048 00000 n0000018204 00000 n0000018291 00000 n0000018366 00000 n0000019556 00000 n0000019613 00000 n0000023090 00000 ntrailer>startxref116%%EOF
Surface Logix Frequently Asked Questions (FAQ)
When was Surface Logix founded?
Surface Logix was founded in 1999.
Where is Surface Logix's headquarters?
Surface Logix's headquarters is located at 50 Soldiers Field Place, Brighton.
What is Surface Logix's latest funding round?
Surface Logix's latest funding round is Acquired.
How much did Surface Logix raise?
Surface Logix raised a total of $114M.
Who are the investors of Surface Logix?
Investors of Surface Logix include Nano Terra Inc., Venrock, Intel Capital, ARCH Venture Partners, CW Group and 12 more.
Who are Surface Logix's competitors?
Competitors of Surface Logix include Concert Pharmaceuticals, Numares, Stemina Biomarker Discovery, Novira Therapeutics, Scynexis and 12 more.
Compare Surface Logix to Competitors
Total Pharmaceutical Care, Inc. offers home healthcare and infusion therapy services
Oxagen is a biopharmaceutical company that develops small molecule drugs for inflammatory and respiratory diseases.
Numares develops and markets in-vitro diagnostic tests with CE-marking and integrated test systems for use in clinical diagnostics and life science research. Its analytic and diagnostic test systems are based on nuclear magnetic resonance (NMR) spectroscopy and numares' proprietary Magnetic Group Signaling (MGS) technology. The company also provides its test systems to the pharmaceutical industry on a fee-for-service basis. Numares was formerly known as LipoFIT Analytic. The company was founded in 2004 and is based in Regensburg, Germany.
PhysioGenix offers pharmacogenetics and physiological genetics products and services
Tequesta Marine Biosciences is a specialty pharmaceutical firm that develops small molecule therepeutic drugs for inflammatory conditions.

Welcome to CHIRAL TECHNOLOGIES, INC., a supplier of columns, bulk stationary phases and separation services for chromatographic enantioselective separations to pharmaceutical, biotechnology, and fine chemicals companies. As users explore the company's site users will find many ways in which having CHIRAL TECHNOLOGIES as their partner can help users in all aspects of chromatographic resolution.
Discover the right solution for your team
The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.